Together, these findings suggest that bortezomib-resistant MM cells, like their sensitive counterparts, may retain their reliance on Mcl-1 for survival, and that targeting P-TEFb represents a potentially effective strategy in this setting. This evidence concerns the gene MCL1 and Miyoshi myopathy.